Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Buys Additional Alnylam Stock

Premium

Alnylam Pharmaceuticals announced this week that its partner Genzyme has exercised an option to buy 344,448 unregistered shares of Alnylam stock for $23 million as part of the companies broad genetic diseases alliance disclosed earlier this year.

In January, the companies announced that they had signed a deal under which Genzyme acquired the rights to Alnylam's existing and future genetic diseases medicines programs in territories outside of North America and Western Europe for the next six years.

In exchange, Genzyme purchased a 12 percent stake in Alnylam, buying about $700 million shares of newly issued stock at $80 apiece. Following Alnylam's issuance of stock to Merck in exchange for that company's RNAi assets, Genzyme was given the option to buy additional Alnylam stock in order to maintain its ownership percentage.

Genzyme exercised the option, buying the additional shares at $66.88 each, the closing price of Alnylam's stock at the time.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.